- | Aridis Pharmaceuticals
Inhaled antibody drug for COVID-19 clears coronavirus in animals
Aridis Pharmaceuticals is working on an inhaled neutralizing antibody for COVID-19 dubbed AR-711, which was discovered using samples from patients who had recovered from COVID-19. The drug successfully cleared signs of SARS-CoV-2 virus from infected hamsters at a far lower dose compared with other experimental monoclonal antibodies, according to results published on preprint site bioRxiv.
- | Fountain Therapeutics
HQ Move Fuels Fountain’s AI Drug Discovery Machine
Fountain Therapeutics’ unique AI discovery platform prompted an invitation from Eli Lilly & Company to move Fountain headquarters to Lilly Gateway Labs. Company CEO Dr. John Dimos is making the most of it.
- | Fountain Therapeutics
SMA, NMOSD and Aging – From Few to Everyone
Moira speaks with Dr. Levi Garraway, the Chief Medical Officer of Genentech about FDA approvals for treatments in two very rare diseases – SMA – Spinal Muscular Atrophy, and NMOSD – Neuromyelitis Optica Spectrum Disorder.
- | Scynexis
Scynexis submits NDA for oral ibrexafungerp for vaginal yeast infection
Scynexis announced today that it has submitted a new drug application to the FDA for oral ibrexafungerp for the treatment of vulvovaginal candidiasis, the second most common cause of vaginitis.
- | Cardiff Oncology
Mark Erlander of Cardiff Oncology, Inc. Discusses KRAS Mutations in Cancer
Mark Erlander, Chief Executive Officer at Cardiff Oncology, Inc. talks KRAS mutations in cancer, and existing products like mCRC, mCRPc and AML, along with three clinical programs including Zytiga-Resistant Metastatic Castration Resistant Prostate cancer (mCRPC); KRAS mutated Metastatic Colorectal Cancer (mCRC) and Relapsed/Refractory Acute Myeloid Leukemia (AML). You can find out more here.
- | Cidara Therapeutics
Antiviral Conjugates – A Novel Treatment and Prevention Strategy for Viral Diseases Including COVID-19
Cidara Therapeutics has adopted key immuno-oncology principles and applied them to infectious disease, enabling the creation of a novel antiviral strategy – antiviral conjugates (AVCs). AVCs are long-acting, bispecific drugs that directly inhibit viral proliferation, whilst simultaneously
- | Vaxart
Oral coronavirus vaccine candidate enters clinical trial
An oral coronavirus vaccine candidate has entered the clinical trial phase, bringing with it a possible option for those wary of needles. Vaxart Inc. announced on Tuesday that the first subject had received a dose of the VXA-CoV2-1 oral tablet in a Phase 1 clinical trial.
- | Cerevance
Developing Novel Treatments for CNS Diseases
Technology Networks recently spoke with Brad Margus, CEO at Cerevance, to find out how the company is addressing key drug development challenges. In this industry insight, Margus tells us more about the company’s drug development pipeline and their lead candidate CVN424, which is currently being developed to treat Parkinson’s disease. He also explains how Cerevance’s Nuclear Enriched Transcript Sort sequencing (NETSseq) platform is helping to discover promising targets that could be exploited therapeutically.
